CTI Biopharma is a Seattle Washington-based commercial biopharmaceutical company focused on the
acquisition, development, and commercialization of novel targeted therapies for blood-related cancers
that offer unique options to patients and their healthcare providers. CTI has one FDA-approved product
VONJOTM (pacritinib), a JAK2 and IRAK1 inhibitor.VONJO was approved for use by the FDA on February
28, 2022. Please see full prescribing information at www.VONJO.com. Contact us at (800) 215-2355.